Assertio Holdings shares surge 15.33% after-hours as Q3 sales hit $49.5M, EBITDA jumps to $20.9M, and Rolvidon maintains 43% market share.

Assertio Holdings surged 15.33% in after-hours trading following its Q3 2025 earnings call, which highlighted robust financial growth and strategic progress. Total product sales rose to $49.5 million from $28.7 million year-over-year, driven by strong performance of Rolvidon, which maintained a 43% market share in the Medicare Part B segment. Adjusted EBITDA climbed to $20.9 million from $4.4 million, supported by higher Rolvidon sales and a long-term supply agreement with Omni ensuring stable pricing. The company also reported $93.4 million in cash equivalents and short-term investments as of September 30, 2025, underscoring financial strength. While challenges like generic competition for Indocin and temporary cash flow impacts from Rolvidon sales timing were noted, the earnings call emphasized positive momentum and strategic clarity, including plans to refine promotional strategies for Rovedon and expand awareness of Simpizan’s delivery mechanism. The significant after-hours rally reflects investor optimism over the company’s near-term execution and market position.